BlueRock Launches Phase III Trial of Bemdaneprocel for Parkinson’s Disease

BlueRock Therapeutics, a Bayer subsidiary, has begun its pivotal phase III trial (exPDite-2) of bemdaneprocel, an investigational cell therapy for Parkinson’s disease (PD).

This is the first phase III trial for an allogeneic pluripotent stem cell-derived therapy in PD.

Why It Matters

Parkinson’s disease affects over 10 million people worldwide. It is the second most prevalent neurodegenerative disease and the most common movement disorder. Current therapies manage symptoms but do not alter disease progression.

About the Trial

• Design: Multicenter, randomized, double-blind, sham-controlled.
• Enrollment: ~102 patients with Parkinson’s disease.
• Primary endpoint: Change from baseline to week 78 in “ON-time” without troublesome dyskinesia (16-hour waking day).
• Secondary endpoints: Movement measures, non-motor symptoms, safety, quality of life.

In phase I, bemdaneprocel showed good tolerability and encouraging trends in motor improvement at 24 months. No serious adverse events related to the therapy were reported.

How Bemdaneprocel Works

Bemdaneprocel (BRT-DA01) is designed to replace dopamine-producing neurons lost in PD.

• Derived from human embryonic pluripotent stem cells.
• Implanted surgically into the brain.
• Mature into dopamine neurons.
• Potential to re-form neural networks and restore motor and non-motor function.

The FDA has granted Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations.

Leadership Voices

“People with Parkinson’s urgently need therapies that alter the disease course,”

• Amit Rakhit, MD, MBA, Chief Development & Medical Officer at BlueRock.

“This milestone advances our commitment to transform treatment through innovative therapies,”

• Christian Rommel, PhD, Head of R&D, Bayer Pharmaceuticals.

The Bigger Picture

If successful, the exPDite-2 trial could provide data for regulatory submissions and move PD care toward disease-modifying therapy.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!